Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Anika Therapeutics Inc. (ANIK) vs Emergent Biosolutions Inc. (EBS)

Anika Therapeutics Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. Emergent Biosolutions Inc. is the larger, with a market value of $347.1M against $270.7M — 1.3× the size. Anika Therapeutics Inc. grew revenue faster over the last twelve months: 5.33% against −9.56%. Anika Therapeutics Inc. has the higher net margin (−3.14% vs −23.0%) and the higher return on invested capital (−3.24% vs −5.27%). Across the 21 metrics below, Anika Therapeutics Inc. leads on 11 and Emergent Biosolutions Inc. on 10.

Valuation

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 2.25 0.45 2.25
P/B 1.98 1.03 1.90
Price to free cash flow 483.15 4.07 16.54
EV/EBITDA 508.54 21.47 12.29
EV/Sales 2.16 1.03 2.56
Earnings yield (1.28%) (50.66%) (2.99%)
Free cash flow yield 0.21% 24.57% 0.00%

Profitability

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
Gross margin 62.16% 55.87% 53.94%
Operating margin (4.24%) (8.57%) 0.00%
Net margin (3.14%) (22.96%) 0.00%
Free cash flow margin 0.47% 11.18% 0.00%
Return on equity (2.66%) (40.29%) (0.40%)
Return on assets (2.04%) (13.95%) (3.32%)
Return on invested capital (3.24%) (5.27%) 0.00%

Growth

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 5.33% (9.56%) 10.01%
EPS growth (last fiscal year) 80.16% 125.83% —
Revenue growth, 5-year CAGR (2.86%) (13.74%) 6.74%
Net income growth, 5-year CAGR 0.00% (29.64%) 0.00%

Health

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 1.70 0.05
Current ratio 4.48 5.42 2.31
Net debt to EBITDA 10.80 1.76 0.85

Dividend

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
Dividend yield — 0.79% 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ANIK EBS Drug Manufacturers Specialty & Generic median
Market cap 270.74m 347.12m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack